ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DEPO Depomed, Inc. (delisted)

7.30
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Depomed, Inc. (delisted) NASDAQ:DEPO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 7.30 7.25 7.43 0 01:00:00

Depomed to Report Fourth Quarter Fiscal Year 2017 Financial Results on Tuesday, February 27, 2018

20/02/2018 9:05pm

GlobeNewswire Inc.


Depomed, Inc. (delisted) (NASDAQ:DEPO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Depomed, Inc. (delisted) Charts.

Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2017 financial results on Tuesday, February 27, 2018, after the close of markets. The Company will host a conference call beginning at 4:30 p.m. EST (1:30 p.m. PST) to discuss its results.

Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

Audio Conference Call:

U.S. Dial-in Number:1-844-839-0046
International Dial-in Number: 1-857-270-6032
Conference ID:2157887

An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com. 

INVESTOR AND MEDIA CONTACTS:

Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 ckeenan@depomed.com

Daniel Peisert VP, Business Development dpeisert@depomed.com

1 Year Depomed, Inc. (delisted) Chart

1 Year Depomed, Inc. (delisted) Chart

1 Month Depomed, Inc. (delisted) Chart

1 Month Depomed, Inc. (delisted) Chart

Your Recent History

Delayed Upgrade Clock